On April 9, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that AstraZeneca had registeredOne itemRilvegostomig Combined with Bevacizumab With or Without TremelimumabFirst-line treatment for hepatocellular carcinomaPhase III Study（CTR20251317）. This is also the initiation of the drugFirst Phase III Clinical Trial for Hepatocellular Carcinoma。Screenshot source: Drug Clinical Trial Registration and Information Disclosure PlatformThe primary endpoint of the study isEvaluation of Rilvegostomig in Combination with Tremelimumab（Tiximab)Safety and tolerability of Bevacizumab in all subjects receiving dosing during the safety lead-in period, andEvaluate the effectiveness of Group A compared to Group C by assessing the OS of subjects with advanced HCC.The trial involved a total of 89 institutions, with 310 participants planned for enrollment in China and 1220 participants internationally.Rilvegostomig is a PD-1/TIGIT bispecific antibody, with the highest research progress globally and in China both at Phase III clinical stage. AstraZeneca has laid out multiple indications for Rilvegostomig, among whichBiliary Tract Cancer,
Non-Small Cell Lung Cancer, Gastric CancerHave all entered Phase III clinical trials.Tremelimumab is a human monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4.(CTLA-4)By blocking the activity of CTLA-4, it promotes T-cell activation, triggering an immune response against cancer and promoting cancer cell death. In addition to its approved indications for liver cancer and lung cancer, the drug is currently being evaluated in combination with durvalumab for the treatment of various tumor types, including SCLC.(ADRIATIC)And Bladder Cancer(VOLGA and NILE)etc.Insight database shows that there are only 6 products globallyPD-1/TIGIT Bispecific AntibodyUnder development,Rilvegostomig is the fastest progressing. In addition, there are 3 more products that have entered the clinical stage, 2 of which come from companies in China, respectively.InnoventIBI321 andZelgen Biologics ZG005。
Screenshot source: Insight database
Cover Source:Company LogoDisclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.PR Article Coordination: WeChat insightxbSubmission: WeChat insightxb; Email insight@dxy.cn
Diversified functions, traceable data……Insight Database Web Version Awaits Your Experience'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Click to read the original text,ImmediatelyUnlock！
